RSS
Read the latest headlines about the Viennese and Austrian health and pharmaceuticals industry
Vienna International Health and Pharmaceutical Industry News
IAEA Laboratories in Seibersdorf - A Hub of Scientific Excellence
The laboratories of the International Atomic Energy Agency (IAEA) are located in the town of Seibersdorf, where scientists carry out unique work in support of global peace and development. Located 35 kilometres south of Vienna, the 10 laboratories play an important role in the IAEA’s activities in the areas of nuclear verification, food and agriculture, human health, industrial applications and the environment. Recently Austrian President Van der Bellen paid a visit to Seibersdorf.
Yesterday
Austrian Delegation Seeks to Improve Economic and Political Relations with Jordan
An official visit of President Van der Bellen to Jordan will take place from 17 April to 19 April 2018. The delegation to Amman will be accompanied by an economic mission headed by WKO Vice President Richard Schenz. The economic mission of the WKO is the response of an invitation issued some time ago by the President of the Chamber of Commerce of the Kingdom.
March 8, 2018
Life Sciences Field is Booming in Vienna
Nine percent revenue growth, five percent increase in the workforce and a large increase in business startups - Vienna as a location for life science businesses is attracting companies at a rate never seen before.
October 14, 2015
Valneva Completes EUR 45 Million Capital Increase
The listed biotechnology company Valneva SE announces the completion of its capital increase with shareholders preferential subscription rights launched on January 12th, 2015. Valneva estimates net proceeds of EUR 42 millions from 18.2 million offered new shares. The new ordinary shares will be traded on Euronext and on the Prime Market segment of the Vienna Stock Exchange. The financing will mainly be used for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral.
February 4, 2015
Pfizer's Agreement To Acquire Baxter’s Portfolio Of Marketed Vaccines Includes Facility in Austria
Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.
August 1, 2014
Austrian Export Award 2014 for Above-Average Export Commitment
As part of a festive gala evening in Vienna's Museumsquartier, the Austrian Export Prize 2014 has been awarded by the Federal Minister for Science, Research and Economics, Reinhold Mitterlehner, and the President of the Economic Chamber Austria (WKO) Christoph Leitl.
June 26, 2014
Semperit AG Holding: High Ethical and Social Standards at Sempermed in Thailand
The Semperit Group is committed to high ethical and social standards as well as good working conditions for all its employees around the world. An independent audit carried out to verify adherence to the Code of Conduct of the Business Social Compliance Initiative (BSCI) shows that this also applies to the Siam Sempermed glove production facilities in Hatyai, Thailand.
June 6, 2014
Mitterlehner: Romania Offers New Chances for Austrian Economy
Austrian Economy Minister Reinhold Mitterlehner met his Romanian counterpart Varujan Vosganian in Vienna.
June 25, 2013
Austria: Government Agrees on Stimulus Package
Startled by construction company Alpine’s insolvency, the Austrian government has agreed on the fiercly discussed stimulus package. An amount of € 800m is required additionally.
June 25, 2013
Austria: Biggest Investor in Serbia
Serbia encourages Austrian enterprises to further invest in Serbian industries.
May 16, 2013
67 % of Estonians Work in Service Sector
According to the data of the 2011 Population and Housing Census (PHC 2011) of Statistics Estonia, 67% of persons employed in Estonia worked in service sector, 29% in industrial sector and only 4% in primary sector.
March 30, 2013
EU’s Austerity Cuts Adverse to Health
EU’s austerity measures negatively affect citizen’s health, is the result of a health study carried out by “The Lancet”. The Commission was supposed to examine the political effects.
March 27, 2013
Strikes Paralyze Poland
Protests against government’s changes in education, social and labor policy.
March 27, 2013
Romania: Slight Increase of GDP for 2012 at 0.1 % on Y/Y Comparison
Record decrease at 24.6 % in agriculture, industrial production better off with decrease of 2.4 %. The highest increase was recorded in IT and communication, services and health/social assistance.
March 6, 2013
Latvia: Drop in Industrial Productivity by 3.5 %
Data of the Central Statistical Bureau show that, in comparison with December 2012, industrial production in January 2013 has declined by 3.5 %
March 6, 2013
Slovakia: Gross Domestic Product Rose in Q 4 of 2012
Compared to Q 3 of 2012 this means an increase of 0.2 %, by y/y the GDP rose by 2 %.
March 6, 2013
Austria at Medical Fair Asia 2012
Top medical products “made in Austria” at MEDICAL FAIR ASIA and MEDICAL MANUFACTURING ASIA 2012 from September 12 2012 to September 14 2012 in Singapore.
August 20, 2012
U.S. Forest Laboratories Cooperates with Nabriva
The U.S. pharmaceutical company provides funds of $ 25m to the Austrian Nabriva and secures pre-emptory rights.
June 2, 2012
Baxter Enlarges Viennese Site
The U.S. pharmaceutical group makes investments of € 30m in Vienna. The start of operation of a new production facility is planned in 2014.
May 18, 2012
Intercell Completes Equity Private Placement
The Austrian pharmaceutical company raises funds of € 15.2m at a price of € 2.30 per new share - bringing total volume of combined debt and equity financing to € 35.2m.
May 15, 2012
Intercell Remains in the Loss Area
The Austrian pharmaceutical company recorded a net loss of € 8.1m in the first quarter of 2012 after € 11.3m in the first quarter of 2011.
May 8, 2012
Canadian Valeant Buys Assets of Gerot Lannach
The Austrian drugmaker Gerot Lannach sells its acetylsalicylic acid business in Russia. The sale price amounts to $ 185m.
March 13, 2012
Sanochemia Announced Scanlux Market Entry in Columbia
The Austrian pharmaceutical company announced the market entry of Scanlux in Columbia. Further approvals are targeted in Costa Rica, El Salvador, Venezuela and Paraguay.
March 7, 2012
Intercell Does Not Leave the Loss zone
The Austrian pharmaceutical company announces preliminary full year 2011 financial results. Losses totaled € 29m.
March 6, 2012
Slight Improvement in Sanochemia´s Results
The Austrian pharmaceutical company could increase sales by 12% in the first quarter of 2011/12. Sanochemia could reach small profits again.
February 15, 2012
Intercell Plans to Achieve Turnaround in 2014
The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.
February 6, 2012
Slightly Positive Results at Sanochemia
The Austrian pharmaceutical company raised revenues by 26%. Profits amount to € 0.7m.
January 26, 2012
Too Little Competition for Energy and Pharmaceuticals
According to the Austrian institute of economic research (WIFO), electricity, energy and pharmaceuticals are too expensive.
January 2, 2012
New Chairman for Intercell’s Supervisory Board
Thomas Szucs succeeds Michael Gréco who remains on the Supervisory Board of the Austrian pharmaceutical company.
December 30, 2011
Sanochemia Achieves Turnaround
The Austrian pharmaceutical company could turn net results and EBIT into the profit zone. Sales were up too.
December 19, 2011
Intercell Receives Approval for Vaccine in India
The Austrian pharmaceutical company achieved an important milestone in the roll-out of its Japanese Encephalitis vaccine in endemic countries.
November 10, 2011
Intercell Still Reports Losses
The Austrian pharmaceutical company could reduce its net losses from € 50.8m to € 20.62m. For the full year the net loss expectations ranges up to € 40m.
November 8, 2011
Full Order Books For VTA
The Austrian water technology company expects a substantial rise in sales for 2012. Recently an order from Indonesia has been recorded.
October 30, 2011
Intercell Continues Development of Vaccines
The Austrian pharmaceutical company announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections.
October 24, 2011
Intercell: EU Invests € 30m in Research Program
The Austrian pharmaceutical company will receive co-funding for a collaborative research project from the European Union.
September 29, 2011
Intercell Looking for Private Equity Shareholder
According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.
September 27, 2011
Sanochemia´s Purchase of Alvetra & Werfft Completed
The Austrian pharmaceutical group acquires the former subsidiary again for € 5.2m.
September 21, 2011
Intercell Successfully Completes Vaccine Study in India
The Austrian biotech company achieved an important step in the licensure process of a vaccine for children.
September 16, 2011
Upper Austrian PAA Laboratories Acquired by GE Healthcare
The Pasching-based cell culture company will combine with the global provider of medical technologies and services. The deal is expected to close in the third quarter.
August 18, 2011
Intercell: Restructuring Is Progressing
Sales of the company’s only product on the market increased by 85% in the first six months of the year. Net loss was down 44.2%.
August 16, 2011
ugichem Closes € 2m Financing Round
The Tyrolean biotech company secured funding from two major investors and a research grant from the Austrian Research Promotion Agency.
August 9, 2011
Intercell Is Looking for Financial Investors
The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.
July 19, 2011
Intercell: “We Will Stabilize Our Share Price”
The Austrian biotech company recorded a dramatic drop in its share price. The CEO remains optimistic and promises stabilization.
June 21, 2011
Intercell to Cut Jobs and Research Budget
The share price plunged by more than 30% after the Austrian pharmaceutical company had announced the termination of a vaccine study.
June 8, 2011
Sanochemia Confirms the Turnaround and Returns to Profitability
Sanochemia reports a profit and puts the focus on market expansion. Revenue increased by 20 percent year-on-year.
May 13, 2011
Intercell: Sale Is No Longer Ruled Out
The new CEO of the Austrian pharmaceutical company, Thomas Lingelbach intends to implement a new strategy for the company. A sale is possible.
May 11, 2011
Lingelbach New CEO for Intercell
Intercell announces new management structure: Thomas Lingelbach appointed new CEO; new Supervisory Board members proposed.
May 5, 2011
Intercell starts a confirmatory clinical study using the Vaccine Enhancement
Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches
May 4, 2011
Sanochemia: Capital Increase Disappointing
The Austrian pharmaceutical company could not meet its own expectations regarding the capital increase. A strategic investor bailed out.
April 18, 2011
Intercell: Vaccine Development to Suspend
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.
April 11, 2011
Fast News Search
This category only
